On July 24, 2023, Vital Biosciences announced that they raised around US$18 million in a Series A financing round led by Lachy Groom and Northpond Ventures. This brings the company’s total funding to date US$48 million.
Vital Biosciences is working on a new technology that can utilize a few drops of blood for a 50 lab-grade tests in 20 minutes. The “VitalOne” is the core of their business which is a device that can run three tests including hematology, clinical chemistry and immunoassay.
Vital Biosciences, founded in 2019, aims to reinvent lab testing to provide tools for patients to monitor their health.
Osler, Hoskin & Harcourt LLP advised Vital Bioscience with a team consisting of Chad Bayne, Gary Marshall and Nataly Dil (Emerging and High Growth Companies).